A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
Inclusion until disease progression
No
Lynne A. Bui, MD
Study Director
Exelixis, Inc.
United States: Food and Drug Administration
XL999-202
NCT00277290
January 2006
November 2006
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
California Cancer Care, Inc. | Greenbrae, California 94904-2007 |
University of Chicago | Chicago, Illinois 60637 |
Hematology/Oncology Associates of the Treasure Coast | Port St. Lucie, Florida 34952 |
Joliet Oncology-Hematology Associates, Ltd | Joliet, Illinois 60435 |
Harry and Jeanette Weinberg Cancer Institute at Franklin Square | Baltimore, Maryland 21237 |
Bradley Cohen | New City, New York 10956 |